

SN BioScience, Boryeong ink licensing agreement of first generic of anti-cancer drug Abraxane in Korea

30 January 2023 | News

Global tech-transfer expected to US, Japan, and Europe



Biotech startup SN BioScience and pharma major Boryeong have signed a domestic manufacturing technology transfer and co-development contract for the albumin nanoparticle anti-cancer drug developed by SN BioScience for the first time in Korea and the fourth time in the world.

Through this contract, Boryeong will have exclusive manufacturing and distribution rights in Korea for "SNA-001." SN BioScience will receive milestones and double-digit royalties according to the development stage.

SN BioScience also signed a domestic distribution agreement with Boryeong in February 2021 for SNB-101, a polymer nanoparticle new drug, and expects a variety of cooperations in the field of anti-cancer drugs in the future.

"SNA-001" is a product that electrostatically binds cytotoxic anti-cancer drugs to albumin using albumin present in human blood as a drug carrier. Abraxane is a global blockbuster first developed by Abraxis BioScience Inc (acquired by Celgene who became a subsidiary of BMS), with sales of \$1.5 billion worldwide in 2020.

SN BioScience is discussing the technology transfer with global leading pharmaceutical companies in the United States, Japan, and Europe, while on the other hand, it is discovering new indications by applying albumin-based nanoparticle platforms to various anti-cancer drugs. The company is also planning to file phase 1 IND for two to three new nanoparticle anti-cancer drugs in the second half of this year.